Literature DB >> 1385524

Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.

F Martinon1, H Gras-Masse, C Boutillon, F Chirat, B Deprez, J G Guillet, E Gomard, A Tartar, J P Levy.   

Abstract

In vivo priming of CTL requires the association with MHC class I molecules of peptides derived from the processing of endogenously produced proteins. Immunization with exogenous proteins or peptides rarely induces MHC class I-restricted CTL unless they are associated with lipidic compounds. The capacity to induce CTL was compared in synthetic peptides and simple lipopeptides containing the Immunodominant MHC class I H-2Dd-restricted T-cell epitope of HIV-1 gp160. In contrast with free peptides in saline, lipopeptides induced strong primary CTL responses in vivo. These CTL were able to lyse cells infected with a recombinant vaccinia virus expressing the HIV-1 env gene. Priming of CTL was also successful when using 16-amino acid lipopeptides as 34-amino acid lipopeptides, suggesting that several epitopes might be included in a single construct. In vivo priming of CTL also requires CD4+ T cell help. We therefore searched for Th cell activation after priming with lipopeptides. Our results show that, as with CTL induction, Th cell activation with lipopeptides did not require mixing with adjuvant. In addition, lipopeptides were also efficient at stimulating antibody-mediated responses. Our results show that a single lipopeptidic construct can induce a total immune response, which is of importance in vaccine development.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385524

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys.

Authors:  B L Perlaza; M Arévalo-Herrera; K Brahimi; G Quintero; J C Palomino; H Gras-Masse; A Tartar; P Druilhe; S Herrera
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

2.  Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.

Authors:  R L Richards; M Rao; N M Wassef; G M Glenn; S W Rothwell; C R Alving
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Authors:  Sharon E Frey; Laurence Peiperl; M Juliana McElrath; Spyros Kalams; Paul A Goepfert; Michael C Keefer; Lindsey R Baden; Michelle A Lally; Kenneth Mayer; William A Blattner; Clayton D Harro; Scott M Hammer; Geoffrey J Gorse; John Hural; Georgia D Tomaras; Yves Levy; Peter Gilbert; Allan deCamp; Nina D Russell; Marnie Elizaga; Mary Allen; Lawrence Corey
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

4.  Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.

Authors:  H Gahéry-Ségard; G Pialoux; B Charmeteau; S Sermet; H Poncelet; M Raux; A Tartar; J P Lévy; H Gras-Masse; J G Guillet
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).

Authors:  E G Hulskotte; A M Geretti; K H Siebelink; G van Amerongen; M P Cranage; E W Rud; S G Norley; P de Vries; A D Osterhaus
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.

Authors:  Valérie Molinier-Frenkel; Renée Lengagne; Florence Gaden; Saw-See Hong; Jeannine Choppin; Hanne Gahery-Ségard; Pierre Boulanger; Jean-Gérard Guillet
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques.

Authors:  L Mortara; H Gras-Masse; C Rommens; A Venet; J G Guillet; I Bourgault-Villada
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.

Authors:  Colleen Olive; Michael Batzloff; Aniko Horváth; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

9.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope.

Authors:  S C Hsu; D M Shaw; M W Steward
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.